Navigation Links
VG Life Sciences Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial
Date:4/4/2013

SAN MARINO, Calif., April 4, 2013 /PRNewswire/ -- VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today positive results from stage two of its Pre-IND Phase I Study to test tolerability and toxicity in patients with advanced stage solid tumors.  The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), developed with VGLS' proprietary metabolic disruption technology (MDT), in combination with sorafenib (marketed as Nexavar®), which was co-developed by Bayer AG and Onyx Pharmaceuticals.

Haig Keledjian , CEO of VG Life Sciences, said, "We are happy to report we attained the safety endpoints we anticipated for our second cohort of patients.  Similar to the positive results we announced previously for our first patient cohort, no significant toxicities were observed at a higher dose of HCQ in combination with sorafenib.  We have begun enrolling patients into the next dosing cohort in this dose-escalation study and look forward to reporting those results in a timely fashion.  We anticipate patient recruitment to accelerate since opening up the enrollment criteria to include patients with breast, colon, lung, liver, pancreatic, and ovarian cancer, and look forward to an ultimate study completion date, from a safety standpoint, of third quarter 2013."

Dr. Tyler Curiel , gynecological oncologist at the Cancer Therapy & Research Center in San Antonio, TX, and principal investigator for the trial said, "Having successfully finished enrollment in cohort two, we have begun treating patients in the third cohort. The safety of our patients is paramount and these results give us the needed information so that we can continue advancing in this next cohort.  The purpose of this study is to establish the safety profile and determine appropriate doses of this combination of anti-cancer drugs."

The trial is supported by a donation from the Scott and White Foundation.  

Details on the Phase 1 study protocol can be downloaded from VG Life Sciences' website and viewed here.  Additional information on the trial can be found at www.clinicaltrials.gov

About VG Life Sciences, Inc.
Founded in 1994, San Marino, California-based VG Life Sciences, Inc. is a biotech company researching treatments for drug-resistant cancer, Lyme disease, Strep, Staph and Sepsis, and HIV/AIDS.  The company's current drug candidates are based on two exclusively licensed platform technologies: Metabolic Disruption (MDT) and Targeted Peptides (TPT); and are covered by the company's portfolio of more than 60 patents.  A physician-initiated Phase I clinical trial of VG Life Sciences' MDT compound in combination with Nexavar™ is ongoing at the Cancer Therapy and Research Center of The University of Texas Health Science Center at San Antonio in patients with refractory or relapsed solid tumors. For more information, visit www.VGLifeSciences.com.

A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform.  

Safe Harbor Statement and Forward-Looking Statements

This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences or any other person that the objectives and plans of VG Life Sciences will be achieved.

VG Life Sciences Contact:
Haig Keledjian , Founder, CEO & President
626-334-5310

For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm , Ph.D. / Andrew Mielach
jdrumm@tiberend.com; 212-375-2664
amielach@tiberend.com; 212-375-2694

 


'/>"/>
SOURCE VG Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
2. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
3. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
4. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
5. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
6. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
7. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
8. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
9. PointCross Life Sciences SENDBox and SEND-as-a-Service Prepare Pharma Companies to Comply with the FDAs Upcoming e-Data Submission Mandate
10. For International Life Sciences, Biotech and Pharmaceutical Events, Top Executives Turn to Global Information
11. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
Breaking Medicine News(10 mins):